Evaluation of C-Scan Capsule in Identifying Subjects With Elevated Risk of Colon Polyps
Study Details
Study Description
Brief Summary
The main objective of the study is to determine the ability of the C-Scan system to identify subjects who are at elevated risk for colon polyps. This will be evaluated by comparing the C-Scan data to colonoscopy data. The C-Scan procedure is therefore performed before the colonoscopy procedure, in order to compare these tests and evaluate the C-Scan system's effectiveness.
During the C-scan procedure, Subjects will be asked to come for an appointment in a clinic. during this appointment, The C-Scan Track will be attached to the subject's back. Subjects then will be asked to swallow the C-Scan capsule and will be released from the clinic to their routine. Subjects will be asked to ingest contrast agent fluid and fiber pills starting 48 hours before capsule swallowing, up to capsule natural excretion.
Standard colonoscopy procedure will be performed within 60 days following the C-Scan Cap swallowing.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: C-Scan System All study participants will undergo the C-Scan System procedure, followed by a standard of care optical colonoscopy |
Device: C-Scan System
Subjects will be provided with contrast agent and dietary fiber pills, and instructed to start intake approximately 48 hours prior to the planned C-Scan procedure start. C-Scan system intervention includes ingestion of the C-Scan Cap and attachment of the C-Scan track to the subject's lower back. The subject is required to keep the C-Scan Track attached to the lower back and to continue intake of contrast agent and dietary fiber pills until the C-Scan Cap's natural excretion. Standard of care optical colonoscopy will be performed within 60 days from the C-Scan Cap ingestion.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Demonstrate the accuracy of the C-Scan system in identifying subjects with colon polyps comparing to optical colonoscopy (OC). [60 days]
For each subject the primary efficacy endpoints are dichotomous diagnosis using the C-Scan device (Test) and optical colonoscopy (Reference standard). Reference standard will be considered "positive" ("1") if at least one polyp of at least 6 mm is found. Test will be considered with elevated risk for polyps ("1") if either at least one polyp of at least 6 mm is found or long WGTT* occurred. The above endpoints will be used to calculate sensitivity and specificity examined in the primary analysis. *Long WGTT is defined as more than 73 hours for male and more than 97 hours for female.
Secondary Outcome Measures
- Negative predictive value for ruling out polyps of at least 10 mm. [60 days]
Reference standard will be considered "positive" ("1") if at least one polyp of at least 10 mm is found.
- Sensitivity of C-Scan for detecting polyps of at least 10mm. [60 days]
Reference standard will be considered "positive" ("1") if at least one polyp of at least 10 mm is found.
- Demonstrate the safety of the C-Scan System [7±3 days from capsule excretion]
Frequency of patients who experienced device or procedure related serious adverse events up to 7±3 days from capsule excretion. In addition, AEs and SAEs will be presented by severity and relation to device and procedure.
- Demonstrate subjects' satisfaction and usability with the C-Scan System [7±3 days from capsule excretion]
This will be assessed via a descriptive analysis using a questionnaire
- Demonstrate subjects' satisfaction with the C-Scan System compared to optical colonoscopy [4-10 days post colonoscopy]
This will be assessed via a descriptive analysis using a questionnaire
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subjects 50-75 years old
-
Able to provide a signed informed consent.
-
Willing and able to comply with the specified study requirements and can be contacted by telephone.
-
Scheduled for colonoscopy procedure no later than 60 days after C-Scan ingestion
-
Maximal abdominal circumference < 125 cm.
Exclusion Criteria:
-
Subject who is not a suitable candidate for a colonoscopy
-
Known history of dysphagia or other swallowing disorders.
-
History of the following:
-
Colorectal polyps
-
A personal history of CRC
-
A family history of CRC or adenomatous polyps diagnosed in a relative before 60 years of age
-
A history of inflammatory bowel disease of significant duration
-
One of two (2) hereditary syndromes
-
Known motility disorders:
-
Chronic Constipation: less than three (3) bowel movements/week, without the use of laxatives within the last 3 months.
-
Ongoing diarrhea defined as passage of loose or watery stools at least three times within 24-hour
-
Delayed gastric emptying.
-
Known IBD (Crohn's, Ulcerative Colitis)
-
Prior history of gastrointestinal tract surgery.
-
Prior history of abdominal surgery that might cause bowel strictures leading to capsule retention, as determined by a physician
-
Any condition believed to have an increased risk for capsule retention, known strictures, known bowel adhesion or 'obstacles' to free passage of the capsule (such as diverticulosis, intestinal tumors, radiation enteritis) or incomplete colonoscopies as determined by a physician.
-
Significant change in diameter and frequency of stool within the last 3 months.
-
GI bleeding within the last 3 months i.e., rectal outlet bleeding, hematochezia or melena.
-
Implanted cardiac device or any other implanted active device
-
Known sensitivity to iodine
-
Acute kidney failure
-
Known condition which precludes compliance or is contraindicated with study and/or device instructions.
-
Any procedure requiring contrast agent, or which may introduce electronic interference (such as magnetic resonance imaging, DEXA scan) or an imaging procedure pre-scheduled within 14 days of C-Scan ingestion
-
Nuclear imaging procedure within the four (4) weeks preceding the C-Scan procedure.
-
Known condition of opioid use disorder and/or alcoholism.
-
Women who are either pregnant or nursing at the time of screening (to be verified by urine or serum pregnancy test for woman of child- bearing potential who are not post-menopausal or undergone surgical sterilization).
-
Concurrent participation in another clinical trail using any investigational drug or device.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mayo Clinic | Rochester | Minnesota | United States | 55905 |
| 2 | NYU Langone Health | New York | New York | United States | 10016 |
Sponsors and Collaborators
- Check-Cap Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- CL-SY-02-0100